Therefore, the anemia of CKD is a potent stimulator of FGF23, as improvement of iron utilization via exogenous EPO administration, or endogenous EPO stimulation in mice treated with a HIF‐PHDi, markedly attenuated the increase in circulating iFGF23 concentrations. Here, EPO is linked to chronic kidney disease.